News

A team of researchers, backed by a grant totaling more than $3 million, will study the feasibility of a nationwide opt-out testing program to detect…

Daily treatment with Mirum Pharmaceuticals’ oral candidate volixibat significantly reduced itching — medically known as pruritus — and fatigue for adults with primary…

Women who develop a subtype of intrahepatic cholestasis of pregnancy (ICP) marked by jaundice — a yellowing of the skin or whites of the…

A protein called semaphorin-3A (SEMA3A) may be a key player in the early cellular mechanisms that cause fat to accumulate in the livers of people…

Levels of neurotensin, a small protein highly present in the gastrointestinal tract, are higher than normal in the blood and liver of biliary atresia…

In ongoing proof-of-concept Phase 2a trials, Arbutus BioPharma’s imdusiran is showing an ability to possibly eliminate chronic hepatitis B infections when used in…

An 8-month-old girl with type 2 progressive familial intrahepatic cholestasis (PFIC2) who was seen at a hospital emergency department with extensive skin bruising was suspected…

High blood levels of the growth differentiation factor 15 (GDF15) protein are associated with an elevated risk of liver cancer and other liver-related complications among…

Nearly all children with Alagille syndrome who received Mirum Pharmaceuticals’ Livmarli (maralixibat) for seven years as part of clinical studies continued to experience…

Bluejay Therapeutics’ investigational antibody therapy BJT-778 appears to safely and effectively lower levels of the hepatitis D virus (HDV) and markers of liver inflammation…